Deep brain stimulation of the globus pallidus internus in the parkinsonian primate: local entrainment and suppression of low-frequency oscillations.
Competing theories seek to account for the therapeutic effects of high-frequency deep brain stimulation (DBS) of the internal globus pallidus (GPi) for medically intractable Parkinson's disease. To investigate this question, we studied the spontaneous activity of 102 pallidal neurons during GPiDBS in two macaques rendered parkinsonian by administration of MPTP. Stimulation through macroelectrodes in the GPi (> or =200 microA at 150 Hz for 30 s) reduced rigidity in one animal and increased spontaneous movement in both. Novel artifact subtraction methods allowed uninterrupted single-unit recording during stimulation. GPiDBS induced phasic (78% of cells) or sustained (22%) peristimulus changes in firing in both pallidal segments. A subset of cells responded at short latency (<2 ms) in a manner consistent with antidromic driving. Later phasic increases clustered at 3- to 5-ms latency. Stimulation-induced decreases were either phasic, clustered at 1-3 ms, or sustained, showing no peristimulus modulation. Response latency and magnitude often evolved over 30 s of stimulation, but responses were relatively stable by the end of that time. GPiDBS reduced mean firing rates modestly and only in GPi (-6.9 spikes/s). Surprisingly, GPiDBS had no net effect on the prevalence or structure of burst firing. GPiDBS did reduce the prevalence of synchronized low-frequency oscillations. Some cell pairs became synchronized instead at the frequency of stimulation. Suppression of low-frequency oscillations did not require high-frequency synchronization, however, or even the presence of a significant peristimulus response. In summary, the therapeutic effects of GPiDBS may be mediated by an abolition of low-frequency synchronized oscillations as a result of phasic driving.
McCairn
Kevin W
KW
Department of Neurobiology, University of Pittsburgh, 4047 BST-3, 3501 Fifth Avenue, Pittsburgh, PA 15261, USA.
Turner
Robert S
RS
D000200:Action Potentials / Q000187:drug effects / Q000502:physiology*; D000465:Algorithms; D000818:Animals; D000978:Antiparkinson Agents / Q000627:therapeutic use; D046690:Deep Brain Stimulation / Q000379:methods*; D004195:Disease Models, Animal; D004550:Elbow / Q000503:physiopathology; D004558:Electric Stimulation / Q000379:methods; D005260:Female; D005917:Globus Pallidus / Q000187:drug effects / Q000473:pathology / Q000502:physiology*; D007980:Levodopa / Q000031:analogs & derivatives / Q000627:therapeutic use; D008252:Macaca fascicularis; D009433:Neural Inhibition / Q000187:drug effects / Q000502:physiology; D009474:Neurons / Q000187:drug effects / Q000502:physiology; D020734:Parkinsonian Disorders / Q000503:physiopathology* / Q000628:therapy*; D010507:Periodicity; D013997:Time Factors
D000978:Antiparkinson Agents; D007980:Levodopa; C035420:levodopa methyl ester